(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/235758 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61P 37/02* (2006.01)
A61P 17/00 (2006.01) *A61K 38/17* (2006.01)
A61P 19/02 (2006.01)

(21) International Application Number:
PCT/US2022/027620

(22) International Filing Date:
04 May 2022 (04.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/183,886	04 May 2021 (04.05.2021)	US
63/197,789	07 June 2021 (07.06.2021)	US
63/242,768	10 September 2021 (10.09.2021)	US
63/249,953	29 September 2021 (29.09.2021)	US
63/326,424	01 April 2022 (01.04.2022)	US


(71) Applicant: **VIELA BIO, INC.** [US/US]; One MedImmune Way, First Floor, Area Two, Gaithersburg, Maryland 20878 (US).

(72) Inventors; and
(71) Applicants: **DRAPPA, Jorn** [US/US]; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **RATCHFORD, Jack**; c/o VIELA BIO, INC., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **HAMMOND, Edward** [US/US]; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(72) Inventors: **REES, William**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **ILLEI, Gabor**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **YAN, Li**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **BROWN, Fraser** et al.; COOLEY LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(54) Title: METHODS OF TREATMENT OF AUTOIMMUNE DISORDERS USING ILT7 BINDING PROTEINS



*Two Week extension under exceptional consideration (delayed labs, drug wash out, COVID-19-related delays) with Medical Monitor approval.

FIG. 1

(57) Abstract: The present disclosure is related to methods of treating an autoimmune disorder in a subject in need thereof comprising administering an immunoglobulin-like transcript 7 (ILT7) binding protein. The present disclosure also relates to methods of reducing plasmacytoid dendritic cells (pDCs), or reducing a type I interferon gene signature (IFNGS) in a tissue, of a subject in need thereof by administering an ILT7-binding protein to the subject.

WO 2022/235758 A1

[Continued on next page]

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*